Heike Antje Marxfeld
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Heike Antje Marxfeld has a total of 144 co-authors. Here are the top co-authors by number of shared publications:
- Bennard van Ravenzwaay
Environmental Sciences Consulting, Altrip, Germany
3 shared publications - Erio Barale-Thomas
Janssen Pharmaceutica NV, Beerse, Belgium
3 shared publications Jonathan Carter
Labcorp Early Development Laboratories, Harrogate, UK
3 shared publications- Vanessa L. Schumacher
Roche Pharmaceutical Research and Early Development (pRED), Roche Innovation Center Basel, Basel, Switzerland
3 shared publications Alex Charlton
Syngenta Crop Protection, Greensboro, NC, USA
2 shared publications- Babunilayam Gangadharan
Bayer S.A.S, Lyon, France
2 shared publications
Latest Publications
- Open Access
- 25 April 2026
- Published by Elsevier in Information Fusion
- Vol. 135
Mitigating Clever Hans strategies in image classifiers through generating counterexamples
- 25 April 2026
- Published by Elsevier in Information Fusion
- Vol. 135
Open AccessMitigating Clever Hans strategies in image classifiers through generating counterexamples
- 6 November 2025
- Published by SAGE Publications in Toxicologic Pathology
- Vol. 54 (2) , 132-148
Nonproliferative and Proliferative Lesions of the Rat and Mouse Female Reproductive System: Revised INHAND Terms for Ovarian Sex Cord/Stromal Lesions
The nomenclature for the female reproductive system was originally published in 2014. After 10 years of practical use, the scientific community requested from the organ working group (OWG) a review of the terminology and criteria for diagnosing ovarian sex cord/stromal lesions. As a result, OWG proposes the use of “sex cord/stromal” as the base terminology for hyperplasia and tumors to better reflect their origin from the sex cord/stroma and make the terminology internally consistent. When no predominant cell type is present, these lesions should then be designated as mixed cell type (e.g., “hyperplasia, sex cord/stromal, mixed,” or “tumor, sex cord/stromal, mixed, benign”). When a clear, predominate cell type is present, the diagnosis should indicate that cell type (e.g., “sex cord/stromal, granulosa cell” or “sex cord/stromal, theca cell”). In the case of tumors, benign or malignant would be applied as appropriate. With these diagnostic revisions, the OWG for the female reproductive system attempts to provide clarification and refinement of criteria to be used for sex cord/stromal lesions.
- 6 November 2025
- Published by SAGE Publications in Toxicologic Pathology
- Vol. 54 (2) , 132-148
Nonproliferative and Proliferative Lesions of the Rat and Mouse Female Reproductive System: Revised INHAND Terms for Ovarian Sex Cord/Stromal Lesions
The nomenclature for the female reproductive system was originally published in 2014. After 10 years of practical use, the scientific community requested from the organ working group (OWG) a review of the terminology and criteria for diagnosing ovarian sex cord/stromal lesions. As a result, OWG proposes the use of “sex cord/stromal” as the base terminology for hyperplasia and tumors to better reflect their origin from the sex cord/stroma and make the terminology internally consistent. When no predominant cell type is present, these lesions should then be designated as mixed cell type (e.g., “hyperplasia, sex cord/stromal, mixed,” or “tumor, sex cord/stromal, mixed, benign”). When a clear, predominate cell type is present, the diagnosis should indicate that cell type (e.g., “sex cord/stromal, granulosa cell” or “sex cord/stromal, theca cell”). In the case of tumors, benign or malignant would be applied as appropriate. With these diagnostic revisions, the OWG for the female reproductive system attempts to provide clarification and refinement of criteria to be used for sex cord/stromal lesions.
- 10 September 2025
- Published by SAGE Publications in Toxicologic Pathology
- Vol. 53 (7) , 602-609
Reliable Identification of Alpha2u-Globulin and Lysozyme Accumulation in Rat Kidney by Label-Free MALDI Mass Spectrometry Imaging
The molecular identification of alpha2 urinary protein in male rat kidneys is crucial in distinguishing human relevant from rat-specific cases of nephropathy caused by protein accumulation. As protein accumulation in the kidney presents uniformly as hyaline eosinophilic droplets, the identification of the causative protein can be very difficult, especially if suitable antibodies are lacking. We describe the successful identification of two morphologically similar protein accumulations (alpha2u protein and lysozyme) in rat kidneys by the matrix-assisted laser desorption ionization mass spectrometry imaging (MALDI MSI). The potential benefits of MSI may extend to other areas of toxicologic pathology, including instances where the protein accumulation must be characterized and the initial steps are unclear or the composition is unknown.
- 10 September 2025
- Published by SAGE Publications in Toxicologic Pathology
- Vol. 53 (7) , 602-609
Reliable Identification of Alpha2u-Globulin and Lysozyme Accumulation in Rat Kidney by Label-Free MALDI Mass Spectrometry Imaging
The molecular identification of alpha2 urinary protein in male rat kidneys is crucial in distinguishing human relevant from rat-specific cases of nephropathy caused by protein accumulation. As protein accumulation in the kidney presents uniformly as hyaline eosinophilic droplets, the identification of the causative protein can be very difficult, especially if suitable antibodies are lacking. We describe the successful identification of two morphologically similar protein accumulations (alpha2u protein and lysozyme) in rat kidneys by the matrix-assisted laser desorption ionization mass spectrometry imaging (MALDI MSI). The potential benefits of MSI may extend to other areas of toxicologic pathology, including instances where the protein accumulation must be characterized and the initial steps are unclear or the composition is unknown.
- 31 May 2025
- Published by SAGE Publications in Toxicologic Pathology
- Vol. 53 (4) , 372-380
Developmental Neurotoxicity (DNT) Studies for Chemical Safety Assessments: Basic Concepts, Experimental Strategies, and Future Directions
The 21st ESTP’s (European Society of Toxicology Pathology) Annual Congress (2024) included a 3-hour scientific session on developmental neurotoxicity (DNT) as applied to chemical safety assessments. Key concepts of this session were to provide an introduction to public concerns around this endpoint, a status update on practical aspects of DNT studies, insights into the use of DNT studies within a regulatory context, as well as some pointers on how to evaluate specific parameters. Understanding the biological and technical variability in performing neuropathology examinations (such as morphometric evaluation) is critical during the course of DNT evaluation. Using thyroid hormone disruption as an example, challenges and pitfalls impacting data interpretation were discussed. Results from the European Centre for Ecotoxicology and Toxicology of Chemicals (ECETOC) Thyroid Task Force regarding thyroid hormone–related neurodevelopmental toxicity in humans and rodents were presented. Histopathological findings in the brain and potential changes in the cochlea of pups associated with thyroid hormone imbalance in dams during pregnancy were shown. A case presentation from an Extended One-Generation Reproductive Toxicity Study (EOGRTS) showing histopathological findings in the absence of changes with morphometric endpoints was included. In conclusion, all session participants underscored the need for integrated data evaluation for DNT risk assessment.
- 31 May 2025
- Published by SAGE Publications in Toxicologic Pathology
- Vol. 53 (4) , 372-380
Developmental Neurotoxicity (DNT) Studies for Chemical Safety Assessments: Basic Concepts, Experimental Strategies, and Future Directions
The 21st ESTP’s (European Society of Toxicology Pathology) Annual Congress (2024) included a 3-hour scientific session on developmental neurotoxicity (DNT) as applied to chemical safety assessments. Key concepts of this session were to provide an introduction to public concerns around this endpoint, a status update on practical aspects of DNT studies, insights into the use of DNT studies within a regulatory context, as well as some pointers on how to evaluate specific parameters. Understanding the biological and technical variability in performing neuropathology examinations (such as morphometric evaluation) is critical during the course of DNT evaluation. Using thyroid hormone disruption as an example, challenges and pitfalls impacting data interpretation were discussed. Results from the European Centre for Ecotoxicology and Toxicology of Chemicals (ECETOC) Thyroid Task Force regarding thyroid hormone–related neurodevelopmental toxicity in humans and rodents were presented. Histopathological findings in the brain and potential changes in the cochlea of pups associated with thyroid hormone imbalance in dams during pregnancy were shown. A case presentation from an Extended One-Generation Reproductive Toxicity Study (EOGRTS) showing histopathological findings in the absence of changes with morphometric endpoints was included. In conclusion, all session participants underscored the need for integrated data evaluation for DNT risk assessment.
- Open Access
- 2 October 2023
- Published by Institute of Electrical and Electronics Engineers (IEEE)
- p. 2599-2607
Towards Fixing Clever-Hans Predictors with Counterfactual Knowledge Distillation
This paper introduces a novel technique called counterfactual knowledge distillation (CFKD) to detect and remove reliance on confounders in deep learning models with the help of human expert feedback. Confounders are spurious features that models tend to rely on, which can result in unexpected errors in regulated or safety-critical domains. The paper highlights the benefit of CFKD in such domains and shows some advantages of counterfactual explanations over other types of explanations. We propose an experiment scheme to quantitatively evaluate the success of CFKD and different teachers that can give feedback to the model. We also introduce a new metric that is better correlated with true test performance than validation accuracy. The paper demonstrates the effectiveness of CFKD on synthetically augmented datasets and on real-world histopathological datasets.
- 2 October 2023
- Published by Institute of Electrical and Electronics Engineers (IEEE)
- p. 2599-2607
Open AccessTowards Fixing Clever-Hans Predictors with Counterfactual Knowledge Distillation
This paper introduces a novel technique called counterfactual knowledge distillation (CFKD) to detect and remove reliance on confounders in deep learning models with the help of human expert feedback. Confounders are spurious features that models tend to rely on, which can result in unexpected errors in regulated or safety-critical domains. The paper highlights the benefit of CFKD in such domains and shows some advantages of counterfactual explanations over other types of explanations. We propose an experiment scheme to quantitatively evaluate the success of CFKD and different teachers that can give feedback to the model. We also introduce a new metric that is better correlated with true test performance than validation accuracy. The paper demonstrates the effectiveness of CFKD on synthetically augmented datasets and on real-world histopathological datasets.
- Open Access
- 3 July 2023
- Published by Taylor & Francis in Critical Reviews in Toxicology
- Vol. 53 (6) , 339-371
Towards a science-based testing strategy to identify maternal thyroid hormone imbalance and neurodevelopmental effects in the progeny – Part IV: the ECETOC and CLE Proposal for a Thyroid Function-Related Neurodevelopmental Toxicity Testing and Assessment Scheme (Thyroid-NDT-TAS)
Following the European Commission Endocrine Disruptor Criteria, substances shall be considered as having endocrine disrupting properties if they (a) elicit adverse effects, (b) have endocrine activity, and (c) the two are linked by an endocrine mode-of-action (MoA) unless the MoA is not relevant for humans. A comprehensive, structured approach to assess whether substances meet the Endocrine Disruptor Criteria for the thyroid modality (EDC-T) is currently unavailable. Here, the European Centre for Ecotoxicology and Toxicology of Chemicals Thyroxine Task Force and CropLife Europe propose a Thyroid Function-Related Neurodevelopmental Toxicity Testing and Assessment Scheme (Thyroid-NDT-TAS). In Tier 0, before entering the Thyroid-NDT-TAS, all available in vivo, in vitro and in silico data are submitted to weight-of-evidence (WoE) evaluations to determine whether the substance of interest poses a concern for thyroid disruption. If so, Tier 1 of the Thyroid-NDT-TAS includes an initial MoA and human relevance assessment (structured by the key events of possibly relevant adverse outcome pathways) and the generation of supportive in vitro/in silico data, if relevant. Only if Tier 1 is inconclusive, Tier 2 involves higher-tier testing to generate further thyroid- and/or neurodevelopment-related data. Tier 3 includes the final MoA and human relevance assessment and an overarching WoE evaluation to draw a conclusion on whether, or not, the substance meets the EDC-T. The Thyroid-NDT-TAS is based on the state-of-the-science, and it has been developed to minimise animal testing. To make human safety assessments more accurate, it is recommended to apply the Thyroid-NDT-TAS during future regulatory assessments.
- 3 July 2023
- Published by Taylor & Francis in Critical Reviews in Toxicology
- Vol. 53 (6) , 339-371
Open AccessTowards a science-based testing strategy to identify maternal thyroid hormone imbalance and neurodevelopmental effects in the progeny – Part IV: the ECETOC and CLE Proposal for a Thyroid Function-Related Neurodevelopmental Toxicity Testing and Assessment Scheme (Thyroid-NDT-TAS)
Following the European Commission Endocrine Disruptor Criteria, substances shall be considered as having endocrine disrupting properties if they (a) elicit adverse effects, (b) have endocrine activity, and (c) the two are linked by an endocrine mode-of-action (MoA) unless the MoA is not relevant for humans. A comprehensive, structured approach to assess whether substances meet the Endocrine Disruptor Criteria for the thyroid modality (EDC-T) is currently unavailable. Here, the European Centre for Ecotoxicology and Toxicology of Chemicals Thyroxine Task Force and CropLife Europe propose a Thyroid Function-Related Neurodevelopmental Toxicity Testing and Assessment Scheme (Thyroid-NDT-TAS). In Tier 0, before entering the Thyroid-NDT-TAS, all available in vivo, in vitro and in silico data are submitted to weight-of-evidence (WoE) evaluations to determine whether the substance of interest poses a concern for thyroid disruption. If so, Tier 1 of the Thyroid-NDT-TAS includes an initial MoA and human relevance assessment (structured by the key events of possibly relevant adverse outcome pathways) and the generation of supportive in vitro/in silico data, if relevant. Only if Tier 1 is inconclusive, Tier 2 involves higher-tier testing to generate further thyroid- and/or neurodevelopment-related data. Tier 3 includes the final MoA and human relevance assessment and an overarching WoE evaluation to draw a conclusion on whether, or not, the substance meets the EDC-T. The Thyroid-NDT-TAS is based on the state-of-the-science, and it has been developed to minimise animal testing. To make human safety assessments more accurate, it is recommended to apply the Thyroid-NDT-TAS during future regulatory assessments.
- 1 June 2023
- Published by SAGE Publications in Toxicologic Pathology
- Vol. 51 (4) , 216-224
Results of the European Society of Toxicologic Pathology Survey on the Use of Artificial Intelligence in Toxicologic Pathology
The European Society of Toxicologic Pathology (ESTP) initiated a survey through its Pathology 2.0 workstream in partnership with sister professional societies in Europe and North America to generate a snapshot of artificial intelligence (AI) usage in the field of toxicologic pathology. In addition to demographic information, some general questions explored AI relative to (1) the current status of adoption across organizations; (2) technical and methodological aspects; (3) perceived business value and finally; and (4) roadblocks and perspectives. AI has become increasingly established in toxicologic pathology with most pathologists being supportive of its development despite some areas of uncertainty. A salient feature consisted of the variability of AI awareness and adoption among the responders, as the spectrum extended from pathologists having developed familiarity and technical skills in AI, to colleagues who had no interest in AI as a tool in toxicologic pathology. Despite a general enthusiasm for these techniques, the overall understanding and trust in AI algorithms as well as their added value in toxicologic pathology were generally low, suggesting room for the need for increased awareness and education. This survey will serve as a basis to evaluate the evolution of AI penetration and acceptance in this domain.
- 1 June 2023
- Published by SAGE Publications in Toxicologic Pathology
- Vol. 51 (4) , 216-224
Results of the European Society of Toxicologic Pathology Survey on the Use of Artificial Intelligence in Toxicologic Pathology
The European Society of Toxicologic Pathology (ESTP) initiated a survey through its Pathology 2.0 workstream in partnership with sister professional societies in Europe and North America to generate a snapshot of artificial intelligence (AI) usage in the field of toxicologic pathology. In addition to demographic information, some general questions explored AI relative to (1) the current status of adoption across organizations; (2) technical and methodological aspects; (3) perceived business value and finally; and (4) roadblocks and perspectives. AI has become increasingly established in toxicologic pathology with most pathologists being supportive of its development despite some areas of uncertainty. A salient feature consisted of the variability of AI awareness and adoption among the responders, as the spectrum extended from pathologists having developed familiarity and technical skills in AI, to colleagues who had no interest in AI as a tool in toxicologic pathology. Despite a general enthusiasm for these techniques, the overall understanding and trust in AI algorithms as well as their added value in toxicologic pathology were generally low, suggesting room for the need for increased awareness and education. This survey will serve as a basis to evaluate the evolution of AI penetration and acceptance in this domain.
- 11 August 2022
- Published by SAGE Publications in Toxicologic Pathology
- Vol. 50 (6) , 793-807
IT/QA and Regulatory Aspects of Digital Pathology: Results of the 8th ESTP International Workshop
Digital toxicologic histopathology has been broadly adopted in preclinical compound development for informal consultation and peer review. There is now increased interest in implementing the technology for good laboratory practice–regulated study evaluations. However, the implementation is not straightforward because systems and work processes require qualification and validation, with consideration also given to security. As a result of the high-throughput, high-volume nature of safety evaluations, computer performance, ergonomics, efficiency, and integration with laboratory information management systems are further key considerations. The European Society of Toxicologic Pathology organized an international expert workshop with participation by toxicologic pathologists, quality assurance/regulatory experts, and information technology experts to discuss qualification and validation of digital histopathology systems in a good laboratory practice environment, and to share the resulting conclusions broadly in the toxicologic pathology community.
- 11 August 2022
- Published by SAGE Publications in Toxicologic Pathology
- Vol. 50 (6) , 793-807
IT/QA and Regulatory Aspects of Digital Pathology: Results of the 8th ESTP International Workshop
Digital toxicologic histopathology has been broadly adopted in preclinical compound development for informal consultation and peer review. There is now increased interest in implementing the technology for good laboratory practice–regulated study evaluations. However, the implementation is not straightforward because systems and work processes require qualification and validation, with consideration also given to security. As a result of the high-throughput, high-volume nature of safety evaluations, computer performance, ergonomics, efficiency, and integration with laboratory information management systems are further key considerations. The European Society of Toxicologic Pathology organized an international expert workshop with participation by toxicologic pathologists, quality assurance/regulatory experts, and information technology experts to discuss qualification and validation of digital histopathology systems in a good laboratory practice environment, and to share the resulting conclusions broadly in the toxicologic pathology community.
- Open Access
- 9 August 2022
- Published by Taylor & Francis in Critical Reviews in Toxicology
- Vol. 52 (7) , 546-617
Towards a science-based testing strategy to identify maternal thyroid hormone imbalance and neurodevelopmental effects in the progeny—part III: how is substance-mediated thyroid hormone imbalance in pregnant/lactating rats or their progeny related to neurodevelopmental effects?
This review investigated which patterns of thyroid- and brain-related effects are seen in rats upon gestational/lactational exposure to 14 substances causing thyroid hormone imbalance by four different modes-of-action (inhibition of thyroid peroxidase, sodium-iodide symporter and deiodinase activities, enhancement of thyroid hormone clearance) or to dietary iodine deficiency. Brain-related parameters included motor activity, cognitive function, acoustic startle response, hearing function, periventricular heterotopia, electrophysiology and brain gene expression. Specific modes-of-action were not related to specific patterns of brain-related effects. Based upon the rat data reviewed, maternal serum thyroid hormone levels do not show a causal relationship with statistically significant neurodevelopmental effects. Offspring serum thyroxine together with offspring serum triiodothyronine and thyroid stimulating hormone appear relevant to predict the likelihood for neurodevelopmental effects. Based upon the collated database, thresholds of ≥60%/≥50% offspring serum thyroxine reduction and ≥20% and statistically significant offspring serum triiodothyronine reduction indicate an increased likelihood for statistically significant neurodevelopmental effects; accuracies: 83% and 67% when excluding electrophysiology (and gene expression). Measurements of brain thyroid hormone levels are likely relevant, too. The extent of substance-mediated thyroid hormone imbalance appears more important than substance mode-of-action to predict neurodevelopmental impairment in rats. Pertinent research needs were identified, e.g. to determine whether the phenomenological offspring thyroid hormone thresholds are relevant for regulatory toxicity testing. The insight from this review shall be used to suggest a tiered testing strategy to determine whether gestational/lactational substance exposure may elicit thyroid hormone imbalance and potentially also neurodevelopmental effects.
- 9 August 2022
- Published by Taylor & Francis in Critical Reviews in Toxicology
- Vol. 52 (7) , 546-617
Open AccessTowards a science-based testing strategy to identify maternal thyroid hormone imbalance and neurodevelopmental effects in the progeny—part III: how is substance-mediated thyroid hormone imbalance in pregnant/lactating rats or their progeny related to neurodevelopmental effects?
This review investigated which patterns of thyroid- and brain-related effects are seen in rats upon gestational/lactational exposure to 14 substances causing thyroid hormone imbalance by four different modes-of-action (inhibition of thyroid peroxidase, sodium-iodide symporter and deiodinase activities, enhancement of thyroid hormone clearance) or to dietary iodine deficiency. Brain-related parameters included motor activity, cognitive function, acoustic startle response, hearing function, periventricular heterotopia, electrophysiology and brain gene expression. Specific modes-of-action were not related to specific patterns of brain-related effects. Based upon the rat data reviewed, maternal serum thyroid hormone levels do not show a causal relationship with statistically significant neurodevelopmental effects. Offspring serum thyroxine together with offspring serum triiodothyronine and thyroid stimulating hormone appear relevant to predict the likelihood for neurodevelopmental effects. Based upon the collated database, thresholds of ≥60%/≥50% offspring serum thyroxine reduction and ≥20% and statistically significant offspring serum triiodothyronine reduction indicate an increased likelihood for statistically significant neurodevelopmental effects; accuracies: 83% and 67% when excluding electrophysiology (and gene expression). Measurements of brain thyroid hormone levels are likely relevant, too. The extent of substance-mediated thyroid hormone imbalance appears more important than substance mode-of-action to predict neurodevelopmental impairment in rats. Pertinent research needs were identified, e.g. to determine whether the phenomenological offspring thyroid hormone thresholds are relevant for regulatory toxicity testing. The insight from this review shall be used to suggest a tiered testing strategy to determine whether gestational/lactational substance exposure may elicit thyroid hormone imbalance and potentially also neurodevelopmental effects.
- 14 July 2021
- Published by SAGE Publications in Toxicologic Pathology
- Vol. 49 (6) , 1206-1228
Proceedings of the 2020 Classic Examples in Toxicologic Pathology XXVII
The histopathology slide seminar “Classic Examples in Toxicologic Pathology XXVII” was held on February 21 and 22, 2020, at the Department of Pathology at the University of Veterinary Medicine in Hannover, Germany, with joint organization by the European Society of Toxicologic Pathology. The goal of this annual seminar is to present and discuss classical and actual cases of toxicologic pathology. This article summarizes the presentations given during the seminar, including images of representative lesions. Ten actual and classical cases of toxicologic pathology, mostly induced by a test article, were presented. These included small intestine pathology and transcriptomics induced by a γ-secretase modulator, liver findings in nonhuman primates induced by gene therapy, drug-induced neutropenia in dogs, device-induced growth plate lesions, polycystic lesions in CAR/PXR double knockout mice, inner ear lesions in transgenic mice, findings in Beagle dogs induced by an inhibitor of the myeloid leukemia cell differentiation protein MCL1, findings induced by a monovalent fibroblast growth factor receptor 1 antagonist, kidney lesions induced by a mammalian target of rapamycin inhibitor in combination therapy, and findings in mutation-specific drugs.
- 14 July 2021
- Published by SAGE Publications in Toxicologic Pathology
- Vol. 49 (6) , 1206-1228
Proceedings of the 2020 Classic Examples in Toxicologic Pathology XXVII
The histopathology slide seminar “Classic Examples in Toxicologic Pathology XXVII” was held on February 21 and 22, 2020, at the Department of Pathology at the University of Veterinary Medicine in Hannover, Germany, with joint organization by the European Society of Toxicologic Pathology. The goal of this annual seminar is to present and discuss classical and actual cases of toxicologic pathology. This article summarizes the presentations given during the seminar, including images of representative lesions. Ten actual and classical cases of toxicologic pathology, mostly induced by a test article, were presented. These included small intestine pathology and transcriptomics induced by a γ-secretase modulator, liver findings in nonhuman primates induced by gene therapy, drug-induced neutropenia in dogs, device-induced growth plate lesions, polycystic lesions in CAR/PXR double knockout mice, inner ear lesions in transgenic mice, findings in Beagle dogs induced by an inhibitor of the myeloid leukemia cell differentiation protein MCL1, findings induced by a monovalent fibroblast growth factor receptor 1 antagonist, kidney lesions induced by a mammalian target of rapamycin inhibitor in combination therapy, and findings in mutation-specific drugs.